Simply Wall St.
Ultragenyx (RARE): Assessing Valuation as Revenue Growth and Clinical Progress Fuel Renewed Investor Interest
📊
AI Sentiment
Positive
7/10
- Home
- RARE
as of 12-02-2025 11:46am EST
$33.52
+$0.15
+0.45%
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Chart Type:
Time Range:
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | NOVATO |
| Market Cap: | 3.2B | IPO Year: | 2014 |
| Target Price: | $85.20 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $25.81 - $50.00 | Next Earning Date: | 11-04-2025 |
| Revenue: | $630,598,000 | Revenue Growth: | 20.63% |
| Revenue Growth (this year): | 19.65% | Revenue Growth (next year): | 23.65% |
AI-Powered RARE Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 17 hours ago
AI Recommendation
hold
Model Accuracy: 78.38%
78.38%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Ultragenyx Pharmaceutical Inc. (RARE)
Horn Howard
Sell
Chief Financial Officer
RARE Oct 13, 2025
Avg Cost/Share
$31.51
Shares
7,942
Total Value
$250,252.42
Owned After
98,227
SEC Form 4
Parschauer Karah Herdman
Sell
EVP and Chief Legal Officer
RARE Sep 12, 2025
Avg Cost/Share
$31.17
Shares
2,450
Total Value
$76,366.50
Owned After
73,271
SEC Form 4
Huizenga Theodore Alan
Sell
SVP, Chief Accounting Officer
RARE Sep 5, 2025
Avg Cost/Share
$31.39
Shares
84
Total Value
$2,636.76
Owned After
50,306
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Horn Howard | RARE | Chief Financial Officer | Oct 13, 2025 | Sell | $31.51 | 7,942 | $250,252.42 | 98,227 | |
| Parschauer Karah Herdman | RARE | EVP and Chief Legal Officer | Sep 12, 2025 | Sell | $31.17 | 2,450 | $76,366.50 | 73,271 | |
| Huizenga Theodore Alan | RARE | SVP, Chief Accounting Officer | Sep 5, 2025 | Sell | $31.39 | 84 | $2,636.76 | 50,306 |
Latest Ultragenyx Pharmaceutical Inc. News
RARE Breaking Stock News: Dive into RARE Ticker-Specific Updates for Smart Investing
Simply Wall St.
Ultragenyx Shares Rally After FDA Updates Are They Priced Right for 2025?
📊
AI Sentiment
Positive
6/10
Insider Monkey
Barclays Remains Cautious on Ultragenyx (RARE), Cites Setrusumab Study Analysis Despite 70% Positive Result Outlook
📊
AI Sentiment
Positive
7/10
Compare RARE vs Leading Stocks
See how RARE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RARE Ultragenyx Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.